Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid
François Durand, Jacques Bernuau, Dominique Pessayre, Didier Samuel, Jacques Belaiche, Claude Degott, Henri Bismuth, Jacques Belghiti, Serge Erlinger, Bernard Rueff, Jean Pierre Benhamou – 1 April 1995 – Isoniazid and pyrazinamide are well‐known hepatotoxic drugs, often used in combination. The aim of this study was to assess the prognostic influence of pyrazinamide on the outcome of fulminant or subfulminant liver failure caused by antituberculous therapy. Eighteen patients with fulminant or subfulminant liver failure due to antituberculous therapy were studied.